Thermo Fisher Scientific Announces Partnership with Pfizer
Tuesday, May 09, 2023
Pfizer and Thermo Fisher Scientific announced they have entered into a collaboration agreement to expand localized access to next generation sequencing-based testing for cancer patients in international markets.
This collaboration agreement will help to increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable.
Under the agreement, Thermo Fisher will identify local labs that will be using the company's NGS technology and ensure they have the necessary infrastructure, trained staff, and quality control measures to meet industry standards for NGS testing services for breast and lung cancer.
Pfizer will explore ways to enable affordable patient access for NGS testing for these types of cancer and work to raise healthcare provider awareness regarding the benefits of advanced testing. The two companies will continue to evaluate opportunities to expand geographically and to expand testing for other types of cancer.
In many parts of the world, access to next-generation sequencing may be limited or unaffordable for cancer patients. This programme aims to improve their treatment journey and help increase their chances for improved outcomes.
